# Safety of HMA-CD20 in Patients With HFrEF

> **NCT03332888** · PHASE2 · UNKNOWN · sponsor: **Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud** · enrollment: 10 (estimated)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03332888
- **Lead sponsor:** Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2021-04-16
- **Final completion:** 2021-07-15
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332888, "Safety of HMA-CD20 in Patients With HFrEF". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03332888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*